Denali Therapeutics, Inc. (DNLI)
21.70
+1.54
(+7.64%)
USD |
NASDAQ |
Apr 15, 16:00
21.69
-0.01
(-0.05%)
After-Hours: 20:00
Denali Therapeutics Research and Development Expense (Annual) : 418.78M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Neurocrine Biosciences, Inc. | 1.016B |
| Protalix Biotherapeutics, Inc. | 19.05M |
| Biogen, Inc. | 1.481B |
| Agenus, Inc. | 79.34M |
| Curis, Inc. | 28.25M |